Literature DB >> 35125723

Impact of HFE-2 and HAMP Gene Variations on Iron Overload in Pediatric Patients with Non-Transfusion Dependent Thalassemia: A Pilot Study.

Niteesh Bharadwaj1, Srinivasan Peyam1, Prateek Bhatia1, Anmol Bhatia2, Reena Das3, Minu Singh1, Deepak Bansal1, Amita Trehan1, Richa Jain1.   

Abstract

Patients with non-transfusion dependent thalassemia (NTDT) develop variable degrees of iron overload. Possible genes which may be implicated in causing iron overload are hepcidin (HAMP) and hemojuvelin (HFE). There is variable data assessing the role of c.-582Y A > G HAMP gene and H63D hotspot in HFE-1 gene in causing iron overload, while role of HFE-2 gene is undetermined. Twenty-five patients with NTDT (≥ 10 years) were assessed for iron overload. Genetic analysis for β-globin, α-globin, HAMP, HFE-2 and C282Y and H63D hotspots in HFE-1 genes was performed. T2*MRI demonstrated elevated LIC in 48% patients. No mutations were detected in HAMP gene or HFE-1 hotspots. Four single nucleotide variations (SNV) were detected in HFE-2 gene in 4 (20%) patients, including a novel SNV, p.Gln315Arg in 2 patients in heterozygous state. This is a likely pathogenic mutation; however, in heterozygous state, it did not lead to iron overload. HAMP and HFE-2 gene variations were infrequently seen in this pilot study, with no significant impact on iron overload. Presence of SNV p.Gln315Argin HFE-2 gene needs to be evaluated in larger sample sizes in our population to determine the incidence in homozygous state and its association with iron overload. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12288-021-01442-9. © Indian Society of Hematology and Blood Transfusion 2021.

Entities:  

Keywords:  Ferritin; Hemojuvelin; Hepcidin; Iron overload; Liver iron concentration; Non-transfusion dependent thalassemia

Year:  2021        PMID: 35125723      PMCID: PMC8804030          DOI: 10.1007/s12288-021-01442-9

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  16 in total

1.  Prevalence of the H63D mutation of the HFE in north India: its presence does not cause iron overload in beta thalassemia trait.

Authors:  Gurjeewan Garewal; Reena Das; Jasmina Ahluwalia; R K Marwaha
Journal:  Eur J Haematol       Date:  2005-04       Impact factor: 2.997

Review 2.  Hereditary hemochromatosis: genetic complexity and new diagnostic approaches.

Authors:  Dorine W Swinkels; Mirian C H Janssen; Jürgen Bergmans; Joannes J M Marx
Journal:  Clin Chem       Date:  2006-04-20       Impact factor: 8.327

3.  Evaluation of the iron status of a population.

Authors:  J D Cook; C A Finch; N J Smith
Journal:  Blood       Date:  1976-09       Impact factor: 22.113

4.  Cholelithiasis and Gilbert's syndrome in homozygous beta-thalassaemia.

Authors:  R Galanello; S Piras; S Barella; G B Leoni; M D Cipollina; L Perseu; A Cao
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

5.  Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.

Authors:  Sara Gardenghi; Maria F Marongiu; Pedro Ramos; Ella Guy; Laura Breda; Amy Chadburn; YiFang Liu; Ninette Amariglio; Gideon Rechavi; Eliezer A Rachmilewitz; William Breuer; Z Ioav Cabantchik; Diedra M Wrighting; Nancy C Andrews; Maria de Sousa; Patricia J Giardina; Robert W Grady; Stefano Rivella
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

6.  Evaluation of the genetic basis of phenotypic heterogeneity in north Indian patients with thalassemia major.

Authors:  Nidhi Sharma; Reena Das; Jasbir Kaur; Jasmina Ahluwalia; Amita Trehan; Deepak Bansal; Inusha Panigrahi; Ram Kumar Marwaha
Journal:  Eur J Haematol       Date:  2010-01-28       Impact factor: 2.997

7.  HFE mutation H63D predicts risk of iron over load in thalassemia intermedia irrespective of blood transfusions.

Authors:  Vineeta Sharma; Inusha Panigrahi; Pankhi Dutta; Seema Tyagi; Ved Prakash Choudhry; Renu Saxena
Journal:  Indian J Pathol Microbiol       Date:  2007-01       Impact factor: 0.740

8.  Non-HFE hemochromatosis.

Authors:  Paulo Caleb Júnior de Lima Santos; Carla Luana Dinardo; Rodolfo Delfini Cançado; Isolmar Tadeu Schettert; José Eduardo Krieger; Alexandre Costa Pereira
Journal:  Rev Bras Hematol Hemoter       Date:  2012

9.  Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.

Authors:  Ali T Taher; John Porter; Vip Viprakasit; Antonis Kattamis; Suporn Chuncharunee; Pranee Sutcharitchan; Noppadol Siritanaratkul; Renzo Galanello; Zeynep Karakas; Tomasz Lawniczek; Jacqueline Ros; Yiyun Zhang; Dany Habr; Maria Domenica Cappellini
Journal:  Blood       Date:  2012-05-15       Impact factor: 22.113

Review 10.  Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.

Authors:  Joseph Sleiman; Ali Tarhini; Rayan Bou-Fakhredin; Antoine N Saliba; Maria Domenica Cappellini; Ali T Taher
Journal:  Int J Mol Sci       Date:  2018-01-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.